IT202200005972A1 - Un metodo in vitro per prevedere la risposta al trattamento del glioblastoma - Google Patents

Un metodo in vitro per prevedere la risposta al trattamento del glioblastoma Download PDF

Info

Publication number
IT202200005972A1
IT202200005972A1 IT102022000005972A IT202200005972A IT202200005972A1 IT 202200005972 A1 IT202200005972 A1 IT 202200005972A1 IT 102022000005972 A IT102022000005972 A IT 102022000005972A IT 202200005972 A IT202200005972 A IT 202200005972A IT 202200005972 A1 IT202200005972 A1 IT 202200005972A1
Authority
IT
Italy
Prior art keywords
predict
response
vitro method
glioblastoma treatment
glioblastoma
Prior art date
Application number
IT102022000005972A
Other languages
English (en)
Inventor
Paolo Aretini
Sara Franceschi
Francesca Lessi
Chiara Maria Mazzanti
Mariangela Morelli
Giovanni Signore
Original Assignee
Fond Pisana Per La Scienza Onlus Fps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Pisana Per La Scienza Onlus Fps filed Critical Fond Pisana Per La Scienza Onlus Fps
Priority to IT102022000005972A priority Critical patent/IT202200005972A1/it
Publication of IT202200005972A1 publication Critical patent/IT202200005972A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
IT102022000005972A 2022-03-25 2022-03-25 Un metodo in vitro per prevedere la risposta al trattamento del glioblastoma IT202200005972A1 (it)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT102022000005972A IT202200005972A1 (it) 2022-03-25 2022-03-25 Un metodo in vitro per prevedere la risposta al trattamento del glioblastoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102022000005972A IT202200005972A1 (it) 2022-03-25 2022-03-25 Un metodo in vitro per prevedere la risposta al trattamento del glioblastoma

Publications (1)

Publication Number Publication Date
IT202200005972A1 true IT202200005972A1 (it) 2023-09-25

Family

ID=82943253

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102022000005972A IT202200005972A1 (it) 2022-03-25 2022-03-25 Un metodo in vitro per prevedere la risposta al trattamento del glioblastoma

Country Status (1)

Country Link
IT (1) IT202200005972A1 (it)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109423A1 (en) * 2007-03-02 2008-09-12 Board Of Regents, The University Of Texas System Multigene assay to predict outcome in an individual with glioblastoma
WO2011109810A2 (en) * 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of predicting high grade gliomas using senescence associated genes
WO2014172627A1 (en) * 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
WO2018177982A1 (en) * 2017-03-30 2018-10-04 Administración General De La Comunidad Autónoma De Euskadi Sox1 as a prognostic and predictive biomarker in the treatment of central nervous system tumours

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109423A1 (en) * 2007-03-02 2008-09-12 Board Of Regents, The University Of Texas System Multigene assay to predict outcome in an individual with glioblastoma
WO2011109810A2 (en) * 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of predicting high grade gliomas using senescence associated genes
WO2014172627A1 (en) * 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
WO2018177982A1 (en) * 2017-03-30 2018-10-04 Administración General De La Comunidad Autónoma De Euskadi Sox1 as a prognostic and predictive biomarker in the treatment of central nervous system tumours

Non-Patent Citations (63)

* Cited by examiner, † Cited by third party
Title
ALDAPE KBRINDLE KMCHESLER LCHOPRA RGAJJAR AGILBERT MR ET AL.: "Nat Rev Clin Oncol", vol. 16, 2019, SPRINGER, article "Challenges to curing primary brain tumours", pages: 509 - 20
ANONYMOUS: "A GeneChip ® Human Genome U133 plus 2.0", 9 December 2004 (2004-12-09), XP055706296, Retrieved from the Internet <URL:https://www.affymetrix.com/support/technical/datasheets/human_datasheet.pdf> [retrieved on 20200618] *
AREEB ZSTUART SFWEST AJGOMEZ JNGUYEN HPTPARADISO L ET AL.: "Sci Rep", vol. 10, 2015, NATURE PUBLISHING GROUP, article "Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma", pages: 1 - 10
ARTEAGA CLSKALA MC, METABOLISM PREDICTS DRUG RESPONSE IN BREAST CANCER, vol. 74, 2015, pages 5184 - 94
BASTOLA SPAVLYUKOV MSYAMASHITA DGHOSH SCHO HKAGAYA N ET AL.: "Nat Commun", vol. 11, 2020, SPRINGER, article "Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy", pages: 1 - 17
BENJAMIN DSATO TCIBULSKIS KGETZ GSTEWART C LL: "Calling Somatic SNVs and Indels with Mutect2", BIORVIX, 2019
BUTLER MPONGOR LSU YTXI LRAFFELD MQUEZADO M ET AL.: "Trends in Cancer", 2020, CELL PRESS, article "MGMT Status as a Clinical Biomarker in Glioblastoma", pages: 380 - 91
CANYON HYDROSUMMARY EOF FPOTENTIAL THEFERRERES XRFONT AR ET AL.: "Inventors are IntechOpen , the world ' s leading publisher of Open Access books Built by scientists , for scientists TOP 1 %", INTECH, vol. 32, 2013, pages 137 - 44
CAO RWALLRABE HKPERIASAMY A: "Multiphoton FLIM imaging of NAD(P)H and FAD with one excitation wavelength", J BIOMED OPT, vol. 25, 2020, pages 1
COLAPRICO A, SILVA TC, OLSEN C, GAROFANO L, CAVA C, GAROLINI D: "Nucleic Acids Res", vol. 43, 29 April 2021, OXFORD UNIVERSITY PRESS, article "ClustVis: A web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap", pages: W566 - 70
DATTA RHEASTER TMSHARICK JTGILLETTE AASKALA MC: "Fluorescence lifetime imaging microscopy: fundamentals and advances in instrumentation, analysis, and applications", J BIOMED OPT, vol. 25, 2020, pages 1, XP055781628, DOI: 10.1117/1.JBO.25.7.071203
EMERY IVETTE F ET AL: "Expression and function of ABCG2 and XIAP in glioblastomas", JOURNAL OF NEURO-ONCOLOGY, SPRINGER US, NEW YORK, vol. 133, no. 1, 21 April 2017 (2017-04-21), pages 47 - 57, XP036269994, ISSN: 0167-594X, [retrieved on 20170421], DOI: 10.1007/S11060-017-2422-Z *
ERKKILA MTREICHERT DGESPERGER JKIESEL BROETZER TMERCEA PA ET AL.: "Macroscopic fluorescence-lifetime imaging of NADH and protoporphyrin IX improves the detection and grading of 5-aminolevulinic acid-stained brain tumors", SCI REP. NATURE RESEARCH, vol. 10, 2020
FADHLULLAH SFBHALIM NBAYEO JYTHO RLYUM PANG BT ET AL.: "Oncogene", vol. 38, 2019, SPRINGER, article "Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness", pages: 5367 - 80
FRANCH-EXPOSITO SBASSAGANYAS LVILA-CASADESUS MHERNANDEZ-ILL AN EESTEBAN-FABRO RDIAZ-GAY M ET AL.: "CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications", ELIFE, vol. 9, 2020, pages 1 - 22
FRAZZI R: "Cell Biosci", vol. 11, 2021, BIOMED CENTRAL, article "BIRC3 and BIRC5: multi-faceted inhibitors in cancer", pages: 0 - 14
GIOMETTO BBOZZA FFARESIN FALESSIO LMINGRINO STAVOLATO B: "Acta Neurochir (Wien", vol. 138, 28 April 2021, SPRINGER, article "Immune infiltrates and cytokines in gliomas", pages: 50 - 6
GOLEBIEWSKA AHAU ACOUDIN ASTIEBER DYABO YABAUS V ET AL.: "Acta Neuropathol", 2020, SPRINGER, article "Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology"
HEGI ME, DISERENS AC, GODARD S, DIETRICH PY, REGLI L, OSTERMANN S: "Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide", CLIN CANCER RES., vol. 10, 2004, pages 1871 - 4, XP003014510, DOI: 10.1158/1078-0432.CCR-03-0384
HU JIEJIANG CHENGCHUANHOKEUNG NGPANG JESSE C S TCYK: "Chromosome 14q may harbor multiple tumor suppressor genes in primary glioblastoma multiforme", CHIN MED J, vol. 115, 2002, pages 1201 - 4
JACOB FSALINAS RDZHANG DYNGUYEN PTTSCHNOLL JGWONG SZH ET AL.: "Cell", vol. 160, 7 May 2021, ELSEVIER INC., article "A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity", pages: 324 - 204
JUNG JINKYU ET AL: "Nicotinamide metabolism regulates glioblastoma stem cell maintenance", JCI INSIGHT, vol. 2, no. 10, 18 May 2017 (2017-05-18), XP093001416, Retrieved from the Internet <URL:https://insight.jci.org/articles/view/90019/version/1/pdf/render.pdf> DOI: 10.1172/jci.insight.90019 *
K. SPECHT ET AL., AM. J. PATHOL., vol. 158, 2001, pages 419 - 29
KARCZEWSKI KJFRANCIOLI LCTIAO GCUMMINGS BBALFOLDI JWANG Q ET AL.: "The mutational constraint spectrum quantified from variation in 141,456 humans", NATURE RESEARCH, vol. 581, 29 April 2021 (2021-04-29), pages 434 - 43, XP037533562, DOI: 10.1038/s41586-020-2308-7
KIPPER FCSILVA AOMARC ALCONFORTIN GJUNQUEIRA AVNETO EP ET AL.: "Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas", INVEST NEW DRUGS, vol. 36, 2018, pages 323 - 31, XP036466707, DOI: 10.1007/s10637-017-0503-7
KOLENC OIQUINN KP: "Evaluating cell metabolism through autofluorescence imaging of NAD(P)H and FAD", ANTIOXIDANTS REDOX SIGNAL, vol. 30, 2019, pages 875 - 89
LE CALVE BRYNKOWSKI MLE MERCIER MBRUYERE CLONEZ CGRAS T ET AL., LONG-TERM IN VITRO TREATMENT OF HUMAN GLIOBLASTOMA CELLS WITH TEMOZOLOMIDE INCREASES RESISTANCE IN VIVO THROUGH UP-REGULATION OF GLUT TRANSPORTER AND ALDO-KETO REDUCTASE ENZYME AKR1C EXPRESSION 1, vol. 12, 28 April 2021 (2021-04-28), pages 727 - 39, Retrieved from the Internet <URL:neoplasia.com>
LEITE DMZVAR BASKOVIC BCIVITA PNETO CGUMBLETON MPILKINGTON GJ: "A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics", FASEB J., vol. 34, 2020, pages 1710 - 27
LINKOUS ABALAMATSIAS DSNUDERL MEDWARDS LMIYAGUCHI KMILNER T ET AL.: "Cell Rep", vol. 26, 2019, ELSEVIERCOMPANY, article "Modeling Patient-Derived Glioblastoma with Cerebral Organoids"
LIVAK KJSCHMITTGEN TD: "Methods", vol. 25, 2001, ACADEMIC PRESS INC., article "Analysis of relative gene expression data using real-time quantitative PCR and the 2-AACT method", pages: 402 - 8
LUKINA MMDUDENKOVA V V.IGNATOVA NIDRUZHKOVA INSHIMOLINA LEZAGAYNOVA E V. ET AL.: "Biochim Biophys Acta - Gen Subj", vol. 1862, 2018, ELSEVIER, article "Metabolic cofactors NAD(P)H and FAD as potential indicators of cancer cell response to chemotherapy with paclitaxel", pages: 1693 - 700
MAHER EABACHOO RM: "Rosenberg's Mol. Genet. Basis Neurol. Psychiatr. Dis.", 2014, article "Glioblastoma"
MAYAKONDA A KH: "Efficient analysis, visualization and summarization of MAF files from large-scale cohort based cancer studies", BIORXIV, 2016
MCDONALD KLTABONE TNOWAK AKERBER WN: "Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation", ONCOL LETT, vol. 9, 2015, pages 2063 - 7
MIRCHIA KSATHE AAWALKER JMFUDYM YGALBRAITH KVIAPIANO MS ET AL.: "Total copy number variation as a prognostic factor in adult astrocytoma subtypes", ACTA NEUROPATHOLOGICA COMMUNICATIONS, vol. 7, 2019, pages 92
NAKAMURA MYONEKAWA YKLEIHUES POHGAKI H: "Promoter Hypermethylation of the RB 1 Gene", GLIOBLASTOMAS, 2001
OUYANG YLIU YWANG ZMLIU ZWU M: "FLIM as a Promising Tool for Cancer Diagnosis and Treatment Monitoring", NANO-MICRO LETT, vol. 13, 11 June 2021 (2021-06-11), pages 133, Retrieved from the Internet <URL:https://link.springer.com/10.1007/s40820-021-00653-z>
PINTO BHENRIQUES ACSILVA PMABOUSBAA H: "Three-dimensional spheroids as in vitro preclinical models for cancer research", PHARMACEUTICS, vol. 12, 2020, pages 1 - 38
PISAPIA DJ: "The updated world health organization glioma classification: Cellular and molecular origins of adult infiltrating gliomas", ARCH PATHOL LAB MED, vol. 141, 2017, pages 1633 - 45
RADKE JKOCH APRITSCH FSCHUMANN EMISCH MHEMPT C ET AL.: "Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients", ACTA NEUROPATHOL COMMUN, vol. 7, 2019, pages 89
RENU DAGGARWAL PCHERUKURI SPRAMILA T: "Molecular Subtypes in Glioblastoma Multiforme: Integrated Analysis Using Agilent GeneSpring and Mass Profiler Professional Multi-Omics Software", AGIL TECHNOL, vol. 1-12, 2015
ROBINSON MDMCCARTHY DJSMYTH GK: "Bioinformatics", vol. 26, 29 April 2021, OXFORD UNIVERSITY PRESS, article "FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features", pages: 139 - 40
SHARICK JTWALSH CMSPRACKLING CMPASCH CAPHAM DLESBONA K ET AL.: "Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment", FRONT ONCOL, vol. 10, 2020, pages 1 - 17
SHERGALIS ABANKHEAD ALUESAKUL UMUANGSIN NNEAMATI N: "Current challenges and opportunities in treating glioblastomas", PHARMACOL REV, vol. 70, 2018, pages 412 - 45
SKALA MCRICHING KMBIRD DKGENDRON-FITZPATRICK AEICKHOFF JELICEIRI KW ET AL.: "In vivo Multiphoton Fluorescence Lifetime Imaging of Proteinbound and Free NADH in Normal and Pre-cancerous Epithelia", J BIOMED OPT, vol. 12, 2007, pages 1 - 19
SKIRIUTE DSTEPONAITIS GVAITKIENE PMIKUCIUNAS MSKAUMINAS KTAMASAUSKAS A ET AL.: "Glioma malignancy-dependent NDRG2 gene methylation and downregulation correlates with poor patient outcome", J CANCER, vol. 5, 2014, pages 446 - 56
SOUBERAN ATCHOGHANDJIAN A: "Practical review on preclinical human 3D glioblastoma models: Advances and challenges for clinical translation", CANCERS (BASEL, vol. 12, 2020, pages 1 - 21
T. E. GODFREY ET AL., J MOLEC. DIAGNOSTICS, vol. 2, 2000, pages 84 - 91
TALEVICH ESHAIN AHBOTTON TBASTIAN BC: "PLoS Comput Biol", 29 April 2021, PUBLIC LIBRARY OF SCIENCE, article "CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing"
TAN ACASHLEY DMLOPEZ GYMALINZAK MFRIEDMAN HSKHASRAW M: "Management of glioblastoma: State of the art and future directions", CA CANCER J CLIN, vol. 70, 2020, pages 299 - 312
TAN ET AL: "Expression of Kir 4.1 in human astrocytic tumors: Correlation with pathologic grade", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 367, no. 4, 11 January 2008 (2008-01-11), pages 743 - 747, XP022449867, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2008.01.014 *
TRINH ALCHEN HCHEN YHU YLI ZSIEGEL ER ET AL.: "Tracking functional tumor cell subpopulations of malignant glioma by phasor fluorescence lifetime imaging microscopy of NADH", CANCERS (BASEL, vol. 9, 2017, pages 1 - 13
VEERIAH SBRENNAN CMENG SSINGH BFAGIN JASOLIT DB ET AL.: "The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers", PROC NATL ACAD SCI USA., vol. 106, 2009, pages 9435 - 40
WALSH AJCOOK RSSKALA MC: "Functional optical imaging of primary human tumor organoids: Development of a personalized drug screen", J NUCL MED, vol. 58, 2017, pages 1367 - 72, XP055749894, DOI: 10.2967/jnumed.117.192534
WALSH ALEX J.COOK REBECCA S.SANDERS MELINDA E.AL, CILIBERTOGENNAROARTEAGACARLOS L: "SC. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer", CANCER RES., vol. 74, 2014, pages 5184 - 5194
WANG DAPENG ET AL: "BIRC3 is a novel driver of therapeutic resistance in Glioblastoma", SCIENTIFIC REPORTS, vol. 6, no. 1, 18 February 2016 (2016-02-18), XP093001888, Retrieved from the Internet <URL:http://www.nature.com/articles/srep21710.pdf> DOI: 10.1038/srep21710 *
WANG LGE JLAN YSHI YLUO YTAN Y ET AL.: "Tumor mutational burden is associated with poor outcomes in diffuse glioma", BMC CANCER, vol. 20, 2020, pages 1 - 12
WANG XWANG YZHANG ZHUANG MFEI YMA J ET AL.: "Discriminating different grades of cervical intraepithelial neoplasia based on label-free phasor fluorescence lifetime imaging microscopy", BIOMED OPT EXPRESS, vol. 11, 2020, pages 1977
WEISSIG VEDEAS M: "Mitochondrial medicine. Preface", METHODS MOL BIOL, 2015, pages 1265
XIUPENGXU ET AL: "Silencing Pre-B-cell leukemia homeobox3 decreases theproliferation ofhuman glioma cells invitro andinvivo", J NEUROONCOL, 30 August 2017 (2017-08-30), pages 453 - 463, XP093001690, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s11060-017-2603-9.pdf> [retrieved on 20221124] *
XU XWANG ZLIU NCHENG YJIN WZHANG P ET AL.: "Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ", INT J ONCOL, vol. 53, 2018, pages 189 - 202
YUAN JXBAFAKIH FFMANDELL JWHORTON BJMUNSON JM: "Quantitative analysis of the cellular microenvironment of glioblastoma to develop predictive statistical models of overall survival", J NEUROPATHOL EXP NEUROL, vol. 75, 2016, pages 1110 - 23
ZHANG PXIA QLIU LLI SDONG L: "Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy", FRONT MOL BIOSCI, vol. 7, 2020, pages 1 - 13

Similar Documents

Publication Publication Date Title
ES2548508T3 (es) Métodos de tratamiento de enfermedades
CY1123367T1 (el) Μεθοδοι και συνθεσεις για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α)
CY1119286T1 (el) Ανταγωνιστες των wnt και μεθοδοι αγωγης
EA201591754A1 (ru) Человеческие антитела к na1.7
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
DE602005014621D1 (de) 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
AR081452A1 (es) APTAMEROS PARA b-NGF Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS MEDIADOS POR b-NGF
EA201690534A1 (ru) Спироциклические соединения в качестве ингибиторов триптофангидроксилазы
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
CU24042B1 (es) Método para la inducción de diferenciación de células madre mesenquimales
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
ES2637386T3 (es) Mejora de la movilidad usando un número más elevado de mediciones de la movilidad durante un período de tiempo
CL2016000228A1 (es) Torre de absorción de un dispositivo de purificación de gases de escape que comprende al menos una instalación de bandeja que proporciona una multiplicidad de aberturas para el gas de escape y el líquido, en donde las aberturas son ajustables individualmente, en grupos o todas juntas en sus respectivas secciones transversales.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
FR2991358B1 (fr) Toile de verre autoadhesive et activable par l’eau
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
AR083212A1 (es) Aparato de hidroprocesamiento de dos etapas, y proceso con fraccionamiento comun
IT202200005972A1 (it) Un metodo in vitro per prevedere la risposta al trattamento del glioblastoma
EA201791280A1 (ru) Способ получения диосмина
IT201700025190A1 (it) Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa
IT1400119B1 (it) Nuovi derivati della mesalazina, processo di sintesi ed uso nel trattamento di malattie infiammatorie intestinali.
FR3010460B1 (fr) Injecteur hydraulique de turbine pelton et methode de demontage partiel d&#39;un tel injecteur
FR2953713B1 (fr) Composition cosmetique capillaire, detergente et lissante, et procede de traitement cosmetique mettant en oeuvre ladite composition
CL2015001420A1 (es) Método ex vivo y kit predictor de respuesta a tratamiento con glucocorticoides (gc) en pacientes portadores de enfermedades inflamatorias, basado en la cuantificación de la razón de cambio de los niveles de las isoformas del receptor de gc.